Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

Two of the year’s biggest investment themes, artificial intelligence and anti-obesity drugs, are finally meeting up, as Novo ...

we're building Novo Nordisk's ability to serve millions more people living with serious chronic diseases in the future." The new facility expects to obtain LEED Gold certification by utilizing ...